Literature DB >> 24483847

Adjuvant chemotherapy after primary treatments for cervical cancer: a critical point of view and review of the literature.

Roberto Angioli1, Daniela Luvero, Alessia Aloisi, Stella Capriglione, Paolo Gennari, Francesca Linciano, Marta Li Destri, Giuseppe Scaletta, Roberto Montera, Francesco Plotti.   

Abstract

Cervical cancer is the second most frequent female malignancy worldwide. Concurrent chemoradiotherapy represents the standard of care for patients with advanced stage cervical cancer, while radical surgery (RS) and radiotherapy is widely used for treating early stage cervical cancer. However, the poor control of micrometastasis, declining operability, the lack of radiotherapy departments and the high incidence of long-term complications due to radiotherapy have brought about the development of different therapeutic approaches such as neoadjuvant chemotherapy followed by RS. Unfortunately, treatment results are still unsatisfactory due to a high recurrence rate and several authors have studied the possibility to add an adjuvant treatment to primary therapy. We reviewed the literature concerning the role of adjuvant chemotherapy in advanced cervical cancer after neoadjuvant chemotherapy followed by RS and after chemoradiotherapy.

Entities:  

Mesh:

Year:  2014        PMID: 24483847     DOI: 10.1586/14737140.2014.866520

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  6 in total

Review 1.  Antiangiogenics and immunotherapies in cervical cancer: an update and future's view.

Authors:  Daniela Luvero; Francesco Plotti; Salvatore Lopez; Giuseppe Scaletta; Stella Capriglione; Roberto Montera; Gianina Antonelli; Sara Ciuffreda; Raffaella Carassiti; Alice Oliveti; Roberto Angioli
Journal:  Med Oncol       Date:  2017-05-05       Impact factor: 3.064

2.  Cisplatin with dose-dense paclitaxel before and after radical hysterectomy for locally advanced cervical cancer: a prospective multicenter phase II trial with a dose-finding study.

Authors:  Maki Tanioka; Satoshi Yamaguchi; Muneaki Shimada; Shoji Nagao; Kazuhiro Takehara; Masato Nishimura; Satoshi Morita; Shunichi Negoro; Kiyoshi Fujiwara; Junzo Kigawa
Journal:  Med Oncol       Date:  2017-07-05       Impact factor: 3.064

3.  Patients treated with neoadjuvant chemotherapy + radical surgery + adjuvant chemotherapy in locally advanced cervical cancer: long-term outcomes, survival and prognostic factors in a single-center 10-year follow-up.

Authors:  Daniela Luvero; Francesco Plotti; Alessia Aloisi; Stella Capriglione; Roberto Ricciardi; Andrea Miranda; Salvatore Lopez; Giuseppe Scaletta; Giovanna De Luca; Pierluigi Benedetti-Panici; Roberto Angioli
Journal:  Med Oncol       Date:  2016-08-30       Impact factor: 3.064

4.  Phenethyl isothiocyanate upregulates death receptors 4 and 5 and inhibits proliferation in human cancer stem-like cells.

Authors:  Dan Wang; Bijaya Upadhyaya; Yi Liu; David Knudsen; Moul Dey
Journal:  BMC Cancer       Date:  2014-08-15       Impact factor: 4.430

5.  Comparison of survival outcomes between radical hysterectomy and definitive radiochemotherapy in stage IB1 and IIA1 cervical cancer.

Authors:  San-Gang Wu; Wen-Wen Zhang; Zhen-Yu He; Jia-Yuan Sun; Yan Wang; Juan Zhou
Journal:  Cancer Manag Res       Date:  2017-12-11       Impact factor: 3.989

6.  Pretreatment Squamous Cell Carcinoma Antigen (SCC-Ag) as a Predictive Factor for the Use of Consolidation Chemotherapy in Cervical Cancer Patients After Postoperative Extended-Field Concurrent Chemoradiotherapy.

Authors:  Guangyu Zhang; Li Miao; Haijian Wu; Youzhong Zhang; Chunli Fu
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.